Asti Emanuele, Siboni Stefano, Lazzari Veronica, Bonitta Gianluca, Sironi Andrea, Bonavina Luigi
Department of Biomedical Sciences for Health, Division of General Surgery, University of Milan, Milan, Italy.
Ann Surg. 2017 May;265(5):941-945. doi: 10.1097/SLA.0000000000001785.
The aim of this study was to identify patients' characteristics that may predict failure and removal of the Linx sphincter augmentation device, and to report the results of 1-stage laparoscopic removal and fundoplication.
The Linx device is a long-term magnetic implant that was developed as a less disruptive and more reproducible surgical option for patients with early-stage gastroesophageal reflux disease (GERD). Removal of the device has been shown to be feasible, but no long-term results of this procedure have been reported yet.
A review of the prospectively collected research database of antireflux surgery was performed to identify all patients who underwent a Linx implant between 2007 and 2015 in our Institution. Demographics, duration of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related Quality of Life scores, esophageal acid exposure, lower esophageal sphincter pressure, number of beads (size) of the implanted device, concurrent crura repair, angle of inclination of the device at postoperative chest film, operative time, postoperative complications, and length of stay were recorded. Data of the explanted patients were compared with those with the device in situ in an attempt to identify factors associated with Linx removal.
Over the study period, 164 patients underwent a laparoscopic Linx implant and had a median follow-up of 48 months [interquartile range (IQR) 36]. Eleven (6.7%) of these patients were explanted at a later date. The estimated removal-free probability at 80 months was 0.91 [confidence interval (CI) 0.86-0.96]. Supine esophageal acid exposure before the index operation was associated with Linx removal (odds ratio 1.05, CI 1.01-1.11, P = 0.037). The main presenting symptom requiring device removal was recurrence of heartburn or regurgitation in 5 patients (46%), followed by dysphagia (n = 4, 37%) and chest pain (n = 2, 18%). In 2 patients, full-thickness erosion of the esophageal wall with partial endoluminal penetration of the device occurred. The median implant duration was 20 months, with 82% of the patients being explanted between 12 and 24 months after the implant. Device removal was most commonly combined with partial fundoplication. There were no conversions to laparotomy and the postoperative course was uneventful in all patients. At the latest follow-up, ranging from 12 to 58 months, the GERD-HRQL score was within normal limits in all patients.
Laparoscopic removal of the Linx device can be safely performed as a 1-stage procedure and in conjunction with fundoplication even in patients presenting with device erosion.
本研究旨在确定可能预测Linx括约肌增强装置失败及移除的患者特征,并报告一期腹腔镜移除及胃底折叠术的结果。
Linx装置是一种长期磁性植入物,是为早期胃食管反流病(GERD)患者开发的一种干扰性较小且更具可重复性的手术选择。已证明该装置的移除是可行的,但尚未报告该手术的长期结果。
对前瞻性收集的抗反流手术研究数据库进行回顾,以确定2007年至2015年在本机构接受Linx植入的所有患者。记录人口统计学资料、症状持续时间和质子泵抑制剂(PPI)治疗情况、GERD健康相关生活质量评分、食管酸暴露情况、食管下括约肌压力、植入装置的珠子数量(尺寸)、同时进行的脚间肌修复、术后胸片上装置的倾斜角度、手术时间、术后并发症及住院时间。将移除装置患者的数据与装置仍在位患者的数据进行比较,以试图确定与Linx移除相关的因素。
在研究期间,164例患者接受了腹腔镜Linx植入,中位随访时间为48个月[四分位间距(IQR)36]。其中11例(6.7%)患者后来移除了装置。80个月时的估计无移除概率为0.91[置信区间(CI)0.86 - 0.96]。初次手术前仰卧位食管酸暴露与Linx移除相关(比值比1.05,CI 1.01 - 1.11,P = 0.037)。需要移除装置的主要症状是烧心或反流复发,共5例(46%),其次是吞咽困难(n = 4,37%)和胸痛(n = 2,18%)。2例患者发生食管壁全层糜烂且装置部分腔内穿透。植入装置的中位持续时间为20个月,82%的患者在植入后12至24个月内移除了装置。装置移除最常与部分胃底折叠术联合进行。所有患者均未转为开腹手术,术后病程平稳。在最新随访中,随访时间为12至58个月,所有患者的GERD - HRQL评分均在正常范围内。
即使在出现装置侵蚀的患者中,腹腔镜下移除Linx装置也可作为一期手术安全进行,并可与胃底折叠术联合进行。